ANI PHARMACEUTICALS, INC Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount
ANI PHARMACEUTICALS, INC (ANIP) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount of -$667.31 thousand for the 12-month period ending 2012-12-31, per its 10-K filed 2013-02-28.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2013-02-28
- ANI PHARMACEUTICALS, INC effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2012 was -$667.31K.
- ANI PHARMACEUTICALS, INC effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2011 was -$1.54M.
- ANI PHARMACEUTICALS, INC effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2010 was -$966.94K.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 12 month |
|---|---|
| 2012-12-31 | -$667.31K 10-K · filed 2013-02-28 |
| 2011-12-31 | -$1.54M 10-K · filed 2013-02-28 |
| 2010-12-31 | -$966.94K 10-K · filed 2013-02-28 |
| 2009-12-31 | -$515.24K 8-K · filed 2013-01-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |